• Hims & Hers Health (NYSE:HIMS) is shifting its weight loss offering from compounded GLP-1 drugs to branded medications from partners such as Novo Nordisk and Eli Lilly.
• The company has entered high-profile partnerships and is investing in technology and diagnostics, which is putting short-term pressure on margins and has led to a return to losses.
• Hims & Hers is planning a major international expansion through the pending acquisition of Australian digital health company Eucalyptus.

Hims & Hers Health, listed on the NYSE as HIMS, operates a telehealth and digital pharmacy platform focused on categories like weight management, mental health, sexual health, and dermatology. The move into branded GLP-1 medications connects the company more directly to one of the most closely watched areas in healthcare, while the Eucalyptus deal extends its reach beyond the United States into new markets.

For you as an investor, this shift reshapes both the growth opportunity and the risk mix around NYSE:HIMS, from product sourcing to regulatory exposure. The coming quarters are likely to show how the partnership-driven GLP-1 model and international expansion affect customer growth, unit economics, and the path back toward profitability.

Stay updated on the most important news stories for Hims & Hers Health by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Hims & Hers Health.

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$25.05, the stock trades about 5.8% below the US$26.61 consensus target, well within the typical uncertainty band.
• ✅ Simply Wall St Valuation: Simply Wall St estimates the shares trade about 62.3% below its fair value, a large valuation gap.
• ✅ Recent Momentum: The stock is up 3.1% over the last 30 days, showing positive short term momentum into the news.

There is only one way to know the right time to buy, sell or hold Hims & Hers Health. Head to the Simply Wall St company report for the latest analysis of Hims & Hers Health's Fair Value..

Key Considerations

• 📊 The pivot to branded GLP 1 drugs and the Eucalyptus deal increase exposure to weight loss and international telehealth, while also tying results more closely to partner execution and integration outcomes.
• 📊 Keep an eye on GLP 1 subscriber growth, gross margin trend as branded drugs ramp, and any updates on Eucalyptus regulatory approvals and integration costs.
• ⚠️ The stock has a highly volatile share price and management has flagged short term margin pressure, so position sizing and time horizon matter.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Hims & Hers Health analysis. Alternatively, you can check out the community page for Hims & Hers Health to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.